Charles Schwab Investment Management Inc. Grows Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)

Charles Schwab Investment Management Inc. boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 14.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 260,120 shares of the company’s stock after purchasing an additional 32,492 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.69% of Keros Therapeutics worth $15,105,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the period. KBC Group NV grew its position in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after acquiring an additional 1,130 shares in the last quarter. Algert Global LLC boosted its position in shares of Keros Therapeutics by 10.6% during the 2nd quarter. Algert Global LLC now owns 15,700 shares of the company’s stock worth $717,000 after purchasing an additional 1,505 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in Keros Therapeutics during the third quarter worth $89,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Trading Up 8.3 %

Shares of Keros Therapeutics stock opened at $70.00 on Friday. Keros Therapeutics, Inc. has a 12-month low of $27.31 and a 12-month high of $73.00. The company’s fifty day simple moving average is $60.32 and its two-hundred day simple moving average is $52.70. The company has a market cap of $2.84 billion, a P/E ratio of -13.44 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million during the quarter. During the same period in the previous year, the business earned ($1.33) EPS. Keros Therapeutics’s quarterly revenue was up 4750.0% on a year-over-year basis. Analysts predict that Keros Therapeutics, Inc. will post -5.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KROS. Wedbush reissued an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Guggenheim reissued a “buy” rating and set a $102.00 price target (up previously from $96.00) on shares of Keros Therapeutics in a report on Wednesday. Bank of America lowered their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Finally, Scotiabank started coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target for the company. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, Keros Therapeutics has an average rating of “Buy” and a consensus target price of $89.56.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.